CNMD vs. INMD, TMDX, LIVN, SLNO, BLFS, ITGR, MASI, AGL, DYN, and TGTX
Should you be buying CONMED stock or one of its competitors? The main competitors of CONMED include InMode (INMD), TransMedics Group (TMDX), LivaNova (LIVN), Soleno Therapeutics (SLNO), BioLife Solutions (BLFS), Integer (ITGR), Masimo (MASI), agilon health (AGL), Dyne Therapeutics (DYN), and TG Therapeutics (TGTX). These companies are all part of the "medical" sector.
CONMED (NYSE:CNMD) and InMode (NASDAQ:INMD) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, risk, institutional ownership, community ranking, dividends, profitability, earnings, valuation and media sentiment.
InMode has a net margin of 40.22% compared to CONMED's net margin of 6.53%. InMode's return on equity of 29.80% beat CONMED's return on equity.
CONMED has a beta of 1.33, suggesting that its stock price is 33% more volatile than the S&P 500. Comparatively, InMode has a beta of 2.16, suggesting that its stock price is 116% more volatile than the S&P 500.
68.0% of InMode shares are owned by institutional investors. 6.8% of CONMED shares are owned by company insiders. Comparatively, 6.9% of InMode shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
InMode received 133 more outperform votes than CONMED when rated by MarketBeat users. Likewise, 75.48% of users gave InMode an outperform vote while only 41.38% of users gave CONMED an outperform vote.
InMode has lower revenue, but higher earnings than CONMED. InMode is trading at a lower price-to-earnings ratio than CONMED, indicating that it is currently the more affordable of the two stocks.
In the previous week, CONMED had 22 more articles in the media than InMode. MarketBeat recorded 30 mentions for CONMED and 8 mentions for InMode. InMode's average media sentiment score of 0.51 beat CONMED's score of 0.38 indicating that InMode is being referred to more favorably in the news media.
CONMED currently has a consensus target price of $107.86, indicating a potential upside of 65.99%. InMode has a consensus target price of $32.80, indicating a potential upside of 92.15%. Given InMode's higher possible upside, analysts clearly believe InMode is more favorable than CONMED.
Summary
InMode beats CONMED on 12 of the 18 factors compared between the two stocks.
Get CONMED News Delivered to You Automatically
Sign up to receive the latest news and ratings for CNMD and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CNMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
